Partial lipodystrophy is a rare condition that affects how fat is distributed throughout the body, and getting the right diagnosis is crucial for managing the health complications that often come with it. Understanding when to seek medical attention and what tests doctors use can help people with unusual fat patterns get the answers and care they need.
Introduction: Who Should Undergo Diagnostics
People who notice unusual changes in how fat is distributed on their body should consider seeking medical evaluation for partial lipodystrophy. This is especially important when fat seems to disappear from certain areas—particularly the arms, legs, and buttocks—while accumulating in others such as the face, neck, or abdomen. These changes can begin at different times depending on the type of partial lipodystrophy, but they often become noticeable around puberty in familial forms of the condition.[1][5]
It is advisable to seek diagnostics when these physical changes are accompanied by metabolic problems. Many people with partial lipodystrophy develop insulin resistance, which means the body’s tissues cannot respond properly to insulin, a hormone that helps control blood sugar levels. This can progress to diabetes, often appearing at a surprisingly young age in people who are not overweight. If you or your child has been diagnosed with diabetes but the typical risk factors don’t apply—such as being young, having a normal body weight, or having an athletic appearance—this could be a signal that lipodystrophy should be investigated.[1][7]
Other warning signs that should prompt diagnostic testing include severely elevated levels of fats in the blood, particularly triglycerides, which are a type of fat that circulates in the bloodstream. When triglyceride levels become extremely high, they can cause visible symptoms such as eruptive xanthomas—small, yellowish bumps on the skin—and can lead to dangerous inflammation of the pancreas called pancreatitis. People may also develop a fatty liver or notice darkened, velvety patches of skin in body folds, a condition called acanthosis nigricans, which is related to high insulin levels.[1][20]
Women should be particularly attentive if they experience irregular menstrual periods, excessive body hair growth, or difficulty becoming pregnant alongside unusual fat distribution. These symptoms can be linked to hormonal changes that occur in certain types of partial lipodystrophy, including polycystic ovary syndrome (PCOS).[1][5]
Family history is another important factor. If you have relatives who experienced similar patterns of fat loss, early-onset diabetes, heart disease at a young age, or unexplained strokes, this increases the likelihood that the condition might be inherited. In such cases, seeking evaluation not only helps the individual but can also identify other family members who may be at risk.[5][9]
Diagnostic Methods
Diagnosing partial lipodystrophy involves a combination of careful clinical observation, imaging studies to assess fat distribution, laboratory tests to evaluate metabolic health, and sometimes genetic testing to identify the underlying cause. Because the condition is rare and can look different in different people, doctors need to use multiple approaches to reach an accurate diagnosis and distinguish it from other conditions.[11][14]
Clinical Examination and Medical History
The diagnostic process typically begins with a detailed medical history and thorough physical examination. The doctor will ask about when changes in fat distribution first appeared, whether they progressed over time, and if any family members have similar features or metabolic problems. During the physical exam, the doctor carefully assesses where fat has been lost and where it has accumulated. In partial lipodystrophy, fat loss commonly affects the limbs and buttocks, giving these areas a very muscular appearance, while excess fat may be visible in the face, neck, back of the shoulders, or deep in the abdomen.[1][5]
The physical examination also looks for signs that are often associated with partial lipodystrophy. These include acanthosis nigricans, which appears as thick, dark, velvety skin in body folds and creases; visible veins due to the lack of overlying fat; and prominent muscles. In women, the doctor may check for signs of excess male hormones, such as increased body hair or enlarged ovaries.[1][7]
Imaging Studies to Assess Fat Distribution
To objectively measure and document fat loss, doctors use various imaging techniques. These tests help confirm that fat is truly missing from certain body areas and can show whether fat has accumulated in places it shouldn’t, such as the liver. Magnetic resonance imaging (MRI) provides detailed pictures of fat tissue throughout the body and can show the exact pattern of fat loss. Computed tomography (CT) scans can also be used to visualize fat distribution and to assess whether fat has built up inside the abdomen or liver. A simpler and more widely available option is dual-energy X-ray absorptiometry (DEXA), a type of scan typically used to measure bone density that can also measure body fat in different regions.[5][11]
In addition to these sophisticated imaging methods, doctors may use basic measurements such as skinfold thickness, where they use calipers to pinch and measure the layer of fat beneath the skin at various body sites. This simple technique can help document where fat is absent.[11]
Laboratory Tests for Metabolic Status
Blood tests are essential for diagnosing partial lipodystrophy and assessing its severity. These tests evaluate the metabolic complications that typically accompany the condition. Key blood tests include measurement of fasting blood sugar and hemoglobin A1c (a measure of average blood sugar over the past three months) to check for diabetes or prediabetes. Lipid panels measure cholesterol and triglyceride levels; people with partial lipodystrophy often have severely elevated triglycerides and low levels of high-density lipoprotein (HDL), the “good” cholesterol.[5][7]
Insulin levels are often measured, particularly after fasting, to assess insulin resistance. The body mass index (BMI) is typically normal despite the metabolic problems, which is an important clue that helps distinguish lipodystrophy from metabolic syndrome in people with obesity.[5][11]
Doctors may also measure blood levels of leptin, a hormone produced by fat tissue that plays a crucial role in regulating appetite and metabolism. People with partial lipodystrophy often have low leptin levels because they have less fat tissue. Similarly, adiponectin, another hormone produced by fat cells that helps regulate blood sugar and fat metabolism, is often reduced.[3][11]
Liver function tests and imaging such as ultrasound help evaluate whether fat has accumulated in the liver, a condition called hepatic steatosis or fatty liver disease. This is common in partial lipodystrophy and can progress to liver inflammation and scarring if not addressed.[1][5]
Genetic Testing
Genetic testing is an important tool for confirming the diagnosis of familial partial lipodystrophy and identifying the specific subtype. Several genes have been linked to different forms of the condition. The most common form, type 2 familial partial lipodystrophy (also called Dunnigan disease), is caused by mutations in the LMNA gene. Other forms are associated with mutations in genes such as PPARG (type 3), PLIN1 (type 4), AKT2, and CIDEC (type 5).[1][5][7]
Genetic testing involves taking a blood sample and analyzing the DNA for mutations in these known genes. Finding a genetic mutation can confirm the diagnosis, provide information about inheritance patterns (which helps assess risk for other family members), and sometimes gives clues about what complications to expect. However, it’s important to know that many people with symptoms of partial lipodystrophy do not have mutations in any of the known genes, suggesting that other causes have yet to be discovered.[5][7]
Distinguishing Partial Lipodystrophy From Other Conditions
One of the challenges in diagnosing partial lipodystrophy is distinguishing it from other conditions that can cause similar features. For example, some people develop partial lipodystrophy as a side effect of medications, particularly certain HIV treatments. This is called acquired partial lipodystrophy and has a different pattern of fat loss. Doctors need to carefully review medication history to identify this possibility.[2][10]
Another form of acquired partial lipodystrophy, called Barraquer-Simons syndrome, typically causes fat loss from the face, neck, arms, and chest during childhood, often following a viral illness. Unlike familial forms, this type may be associated with abnormalities in the immune system, particularly problems with proteins called complement factors. Blood tests measuring complement levels (especially C3) and looking for antibodies can help identify this form.[4][10]
Doctors also need to distinguish partial lipodystrophy from conditions that cause excess fat accumulation without significant fat loss, such as Cushing’s syndrome, and from eating disorders or excessive exercise that can cause low body fat. The combination of selective fat loss, normal BMI, and severe metabolic complications at a young age is the hallmark that points toward lipodystrophy.[1][11]
Diagnostics for Clinical Trial Qualification
Clinical trials are research studies that test new treatments or approaches for managing diseases. For people with partial lipodystrophy, participating in a clinical trial may provide access to promising new therapies. However, to ensure that study results are accurate and that participants are appropriate for the experimental treatment, clinical trials have specific criteria that must be met through diagnostic testing.[14]
Confirming the Diagnosis
Clinical trials typically require confirmed diagnosis of partial lipodystrophy through a combination of clinical assessment and objective measurements. This usually includes documentation of fat loss through imaging studies such as DEXA scans, MRI, or CT scans that show the characteristic pattern of partial lipodystrophy. Some trials specifically require genetic confirmation of a mutation in one of the known lipodystrophy genes, particularly for studies focused on specific genetic subtypes.[5][11]
Metabolic Criteria
Many clinical trials for lipodystrophy treatments focus on addressing the metabolic complications of the condition. Therefore, participants often need to demonstrate specific metabolic abnormalities through laboratory testing. Common requirements include elevated triglyceride levels above a certain threshold, evidence of diabetes or insulin resistance (measured through fasting blood sugar, hemoglobin A1c, or insulin levels), or evidence of fatty liver disease confirmed by imaging or liver enzyme measurements.[3][11]
Some trials may specify that participants must have leptin deficiency, confirmed through blood testing showing leptin levels below a certain value. This is particularly important for trials testing leptin replacement therapy, which aims to supplement the hormone that is lacking due to reduced fat tissue.[3][11]
Baseline Assessments
Before enrolling in a clinical trial, participants undergo comprehensive baseline testing to document their condition at the start of the study. This serves as a comparison point to measure whether the treatment being tested produces improvements. Baseline assessments typically include detailed body composition analysis through DEXA or MRI, comprehensive metabolic panels measuring blood sugar and lipid levels, liver function tests, kidney function tests, and cardiovascular assessments such as blood pressure measurement and sometimes heart ultrasound.[14]
Quality of life questionnaires and physical function tests may also be included, as these help researchers understand not only whether a treatment improves laboratory values but also whether it helps people feel and function better in their daily lives.[14]
Exclusion Criteria
Clinical trials also use diagnostic tests to identify people who should not participate because they have other conditions that could interfere with the study or put them at increased risk. For example, trials may exclude people with severe kidney disease (assessed through blood tests measuring kidney function), advanced liver disease (determined through liver function tests and sometimes liver biopsy), uncontrolled heart disease, or certain other medical conditions. Pregnancy testing is routinely required for women of childbearing age, as many experimental treatments could potentially harm a developing baby.[14]
Monitoring During Trials
Throughout a clinical trial, participants undergo regular diagnostic testing to monitor both the effects of the treatment and any potential side effects. This typically includes repeated blood tests, imaging studies, and physical examinations at scheduled intervals. These ongoing assessments help researchers determine whether the treatment is working and ensure participant safety.[14]
